Navigation Links
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
Date:5/2/2013

IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone.  The MammaPrint test analyzes 70 key genes and accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy.

Case volume grew by more than 140 percent in 2012 and a steep growth trajectory has continued into the first quarter of 2013, noted David Macdonald , Agendia's Chief Executive Officer.

"In addition to this phenomenal growth in a changing healthcare market, Agendia has extended its legacy of leadership in both the clinical and research arenas. The precedent-setting peer-reviewed RASTER publication is the only 5-year outcome study in which MammaPrint was incorporated prospectively into the physician-patient treatment decision. No other gene signature has demonstrated such conclusive effectiveness in accurately guiding the correct decision for patient care. This study has definitely provided a spark in the marketplace," Macdonald said. The RASTER study shows that MammaPrint accurately identifies half of breast cancer patients who can safely forgo chemotherapy with excellent outcome. "That data has given physicians and oncologists throughout the world confidence in the ability of MammaPrint to determine risk, and to guide therapeutic choices."

The success of MammaPrint has also driven growth in the other genomic diagnostic products that make up Agendia's Symphony suite of tests, including BluePrint® and TargetPrint®. More than 85 percent of Agendia customers using MammaPrint also order BluePrint® and TargetPrint® to obtain vital genomic information used in treatment decisions, added Macdonald. 

About MammaPrint:

MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides clinicians with a second generation tool that stratifies a much broader range of early stage breast cancer patients into either a low risk vs. high risk of distant cancer recurrence following surgery. This test goes well beyond the first generation 21-gene test by accurately providing guidance for patients who have the more challenging estrogen receptor low or negative and Her-2 positive patients. Furthermore, MammaPrint evaluates all of the critical molecular pathways involved in the formation of potentially lethal metastasis as opposed the more limited first generation tests. It is equally accurate in formalin fixed-parrafin embedded tissues as it was originally in fresh and frozen tissue. This provides equal access for breast surgeons as well as medical oncologists to offer this critical analysis to patients.

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.

 

 

 


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
2. Agendia Signs Contract with Blue Shield of California
3. Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics
4. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
5. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
6. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a ... consistently been rated one of its top attractions. Fortune 500 companies, such as ... in a unique and intimate team-building experience. , Each event kicks off with an ...
(Date:5/25/2016)... AZ (PRWEB) , ... May 25, 2016 , ... ... Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of the ... 2015. Dr. Fitzmaurice is no stranger to going above and beyond in his ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the use ... W. Stellar has been named by the WEDI Board of Directors as WEDI’s president ... executive leader with more than 35 years of experience in healthcare, association management and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for ... be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly ... tissue regeneration. , The novel method, developed by WPI faculty members Raymond Page, ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
Breaking Biology News(10 mins):